Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.
Authors: Yuan J; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China., Gong J; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China., Peng Z; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China., Liu TS; Medical Oncology Department, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China., Xu H; Oncology Department, Hubei Cancer Hospital, Wuhan, China., Yang J; Clinical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China., Wei J; Oncology Department, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China., Jiang H; Medicine Department, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China., Deng Y; Clinical Oncology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Wang Y; Gastroenterology Ward One Department, Shanxi Cancer Hospital, Taiyuan, China., Qi C; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Department of Early Drug Development Centre, Peking University Cancer Hospital and Institute, Beijing, China., Lyu C; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China., Sun Q; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China., Mu L; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China., Song L; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China., Zhang X; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China. zhangxiaotian@bjmu.edu.cn., Shen L; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China. shenlin@bjmu.edu.cn.
Source: British journal of cancer [Br J Cancer] 2026 Jun 23. Date of Electronic Publication: 2026 Jun 23.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-1827
DOI:10.1038/s41416-026-03511-0